66131-68-8

Basic information

• Product Name: 4-Pyrimidinamine, 2-chloro-N-methyl- (9CI)
• Synonyms: 4-Pyrimidinamine, 2-chloro-N-methyl- (9CI);2-chloro-n-methylpyrimidin-4-amine;2-Chloro-N-methylpyridin-4-amine;2-chloro-N-methylpyrimidin-4-amine(SALTDATA: FREE);2-Chloro-4-(methylamino)pyrimidine;(2-Chloro-pyrimidin-4-yl)-methyl-amine
• CAS NO: 66131-68-8
• Molecular Formula: C₅H₆ClN₃
• Molecular Weight: 143.57424
• EINECS: 604-604-1
• Product Categories: PYRIMIDINE;Amines;Pyrazines, Pyrimidines & Pyridazines;Pyrazines, Pyrimidines & Pyridazines
• Mol File: 66131-68-8.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 317.228 °C at 760 mmHg
• Flash Point: 145.655 °C
• Appearance: /
• Density: 1.338 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 4-Pyrimidinamine, 2-chloro-N-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyrimidinamine, 2-chloro-N-methyl- (9CI)(66131-68-8)
• EPA Substance Registry System: 4-Pyrimidinamine, 2-chloro-N-methyl- (9CI)(66131-68-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41-43
• Safety Statements: 26-36/37-39
• Hazardous Substances Data: 66131-68-8(Hazardous Substances Data)

Usage

General Description

4-Pyrimidinamine, 2-chloro-N-methyl- (9CI) is a chemical compound with the molecular formula C5H6ClN3. It is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. 4-Pyrimidinamine, 2-chloro-N-methyl- (9CI) is a derivative of pyrimidinamine, a heterocyclic organic compound, with a chlorine atom and a methyl group attached to the nitrogen atom. It is known for its unique chemical properties and is utilized in various research and industrial applications. Its structural features make it suitable for use in the development of new drugs and chemical compounds. Additionally, it plays a crucial role in the advancement of organic chemistry and drug discovery.

InChI:InChI=1/C5H6ClN3/c1-7-4-2-3-8-5(6)9-4/h2-3H,1H3,(H,7,8,9)

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 593-51-1 methylamine hydrochloride 
• 74-89-5 methylamine 

Downstream Products

• 955112-52-4 tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate 

Relevant articles and documents

Selectivity, ligand deconstruction, and cellular activity analysis of a BPTF bromodomain inhibitor

Bromodomain and PHD finger containing protein transcription factor (BPTF) is an epigenetic protein involved in chromatin remodelling and is a potential anticancer target. The BPTF bromodomain has one reported small molecule inhibitor (AU1, rac-1). Here, advances made on the structure-activity relationship of a BPTF bromodomain ligand are reported using a combination of experimental and molecular dynamics simulations leading to the active enatiomer (S)-1. Additionally, a ligand deconstruction analysis was conducted to characterize important pharmacophores for engaging the BPTF bromodomain. These studies have been enabled by a protein-based fluorine NMR approach, highlighting the versatility of the method for selectivity, ligand deconstruction, and ligand binding. To enable future analysis of biological activity, cell growth analyses in a panel of cancer cell lines were carried out using CRISPR-Cas9 and (S)-1 to identify cell-based model systems that are sensitive to BPTF inhibition.

USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS

The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inh

2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE

Specific Compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein m, X, R, R2, R3, R, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.